Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lessened by Dakota Wealth Management

Dakota Wealth Management trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,211 shares of the biopharmaceutical company’s stock after selling 2,039 shares during the period. Dakota Wealth Management’s holdings in Gilead Sciences were worth $3,257,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. PCA Investment Advisory Services Inc. acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $25,000. Tompkins Financial Corp raised its holdings in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares in the last quarter. OFI Invest Asset Management acquired a new stake in Gilead Sciences in the third quarter worth approximately $26,000. Fortitude Family Office LLC bought a new position in Gilead Sciences during the 4th quarter valued at $29,000. Finally, Sanctuary Wealth Management L.L.C. bought a new position in Gilead Sciences during the 4th quarter valued at $33,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Down 0.5 %

NASDAQ GILD opened at $67.75 on Tuesday. The stock has a market capitalization of $84.35 billion, a P/E ratio of 15.06, a price-to-earnings-growth ratio of 0.86 and a beta of 0.19. Gilead Sciences, Inc. has a 52 week low of $67.62 and a 52 week high of $87.86. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The stock has a fifty day moving average of $72.61 and a 200-day moving average of $76.78.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter in the prior year, the business earned $1.67 EPS. Gilead Sciences’s revenue was down 3.7% on a year-over-year basis. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.08 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.55%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s payout ratio is 68.44%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.29% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Oppenheimer decreased their price objective on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, February 12th. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Royal Bank of Canada decreased their target price on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 14th. Barclays lowered their price target on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. Finally, StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Hold” and a consensus price target of $85.36.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.